{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:33Z","timestamp":1793224413055,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Biological agents targeting B-cell pathways represent significant advances in systemic lupus erythematosus (SLE) management, yet optimal patient selection remains challenging. This study evaluated whether BAFF\/APRIL expression testing could guide personalized treatment decisions in SLE patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this real-world observational study, we compared two treatment strategies in 86 SLE patients: personalized therapy with telitacicept in BAFF\/APRIL double-positive patients (<jats:italic>n<\/jats:italic>\u202f=\u202f14) versus conventional belimumab therapy without expression testing (<jats:italic>n<\/jats:italic>\u202f=\u202f72). Clinical responses, laboratory parameters, and steroid-sparing effects were assessed at 3 and 6\u202fmonths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Despite having significantly higher baseline disease activity (SLEDAI 18.79\u202f\u00b1\u202f9.34 vs. 8.86\u202f\u00b1\u202f4.3) and more severe proliferative lupus nephritis (Class IV\/IV\u202f+\u202fV in 78.6% vs. 52.8%), the BAFF\/APRIL-guided telitacicept group achieved higher complete response rates (57.1% vs. 48.6%) and lower non-response rates (7.1% vs. 23.6%) compared to the conventional belimumab group. The BAFF\/APRIL-guided group showed more substantial improvements in complement C3 levels (\u0394\u202f=\u202f0.49 vs. 0.24, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and anti-dsDNA antibody reduction (\u0394\u202f=\u202f\u2212177.07 vs \u2212117.00, <jats:italic>p<\/jats:italic>\u202f=\u202f0.028) at 6\u202fmonths. Notably, normalization of immunological parameters was significantly better in the personalized therapy group, with dsDNA abnormalities decreasing from 92.9 to 7.1% (vs 91.7\u201332.5%) and C3 abnormalities from 100 to 28.6% (vs 91.7\u201361.1%). The BAFF\/APRIL-guided group also achieved greater steroid dose reduction at 6\u202fmonths (\u0394\u202f=\u202f\u221235.00 vs \u221225.00\u202fmg, <jats:italic>p<\/jats:italic>\u202f=\u202f0.014).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BAFF\/APRIL expression-guided telitacicept therapy demonstrated superior efficacy in improving clinical responses and laboratory parameters in SLE patients compared to conventional belimumab therapy, despite treating patients with more severe baseline disease. This real-world study provides preliminary evidence supporting BAFF\/APRIL testing as a potential biomarker-driven approach for personalized SLE management, warranting further prospective validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1608085","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:28:24Z","timestamp":1755840504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["BAFF\/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huhai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12660","article-title":"Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: a B-cell immunomics approach","volume":"284","author":"Tipton","year":"2018","journal-title":"Immunol Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000231","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-7","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren\u2019s syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0961203315622820","article-title":"TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ard.2004.029355","article-title":"Raised serum APRIL levels in patients with systemic lupus erythematosus","volume":"64","author":"Koyama","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/ket128","article-title":"Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort","volume":"52","author":"McCarthy","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jmb.2004.08.040","article-title":"The crystal structure of a proliferation-inducing ligand, APRIL","volume":"343","author":"Wallweber","year":"2004","journal-title":"J Mol Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/1756-185X.14678","article-title":"Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus","volume":"26","author":"Guan","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"105291","DOI":"10.1016\/j.ejps.2020.105291","article-title":"Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus","volume":"147","author":"Zhao","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.07.002","article-title":"APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2021-eular.1234","article-title":"ALPN-303, an enhanced, potent dual BAFF\/APRIL antagonist engineered by directed evolution for the treatment of systemic lupus erythematosus (SLE) and other B cell-related diseases","volume":"80","author":"Dillon","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1608085\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:28:25Z","timestamp":1755840505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1608085\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":25,"alternative-id":["10.3389\/fmed.2025.1608085"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1608085","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"article-number":"1608085"}}